Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses

Journal of Interferon and Cytokine Research

Volumn 25, Issue 10, 2005, Pages 632-649

  Tan, Hua ^a   Derrick, Jena ^a   Hong, Jin ^a   Sanda, Corneliu ^b   Grosse, William M ^b   Edenberg, Howard J ^c   Taylor, Milton ^b   Seiwert, Scott ^a   Blatt, Lawrence M ^a  

^a InterMune Inc   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON; GAMMA INTERFERON; GAMMA1B INTERFERON; INTERFERON;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; COMPLEMENT SYSTEM; CYTOTOXIC T LYMPHOCYTE; EXPRESSED SEQUENCE TAG; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INDUCTION; GENETIC TRANSCRIPTION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERFERON STIMULATED GENE; MACROPHAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS INFECTION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-GAMMA, RECOMBINANT; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

HEPATITIS C VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 27144520863     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.632     Document Type: Article

References (72)

1. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000;55:254-287.
2. Brierley MM, Fish EN. IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. 2002;22:835-845.
3. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res. 1992;12:55-59.
4. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 1997;15:563-591.
5. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 1993;11:571-611.
6. Aaronson DS, Horvath CM. A road map for those who don't know Jak-Stat. Science 2002;296:1653-1655.
7. Lau JF, Horvath CM. Mechanisms of type I interferon cell signal-ing and Stat-mediated transcriptional responses. Mt. Sinai J. Med. 2002;69:156-168.
8. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanias LC. Role of p38alpha MAP kinase in type I interferon signaling. J. Biol. Chem. 2004;279:970-979.
9. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol. Ther. 2003;98:129-142.
10. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1998;95: 15623-15628.
11. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004;351: 1206-1217.
12. Loutfy MR, Blatt LM, Siminovitch KA, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290:3222-3228.
13. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003;362:293-294.
14. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve. Clin. J. Med. 2004;71 (Suppl 3):S8-12.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with Interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002;347:975-982.
17. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004;39:1709-1720.
18. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002;99:15661-15668.
19. Fukuda R, Ishimura N, Ishihara S, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S. Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. J. Gastroenterol. 1996;31:806-811.
20. Fukuda R, Ishimura N, Kushiyama Y, Kushiyama Y, Moriyama N, Ishihara S, Nagasawa S, Miyake T, Niigaki M, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J. Hepatol. 1997;26:455-461.
21. Mathai J, Shimoda K, Banner BF, Mori M, Bonkovsky HL, Barnard GF. IFN-α receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J. Interferon Cytokine Res. 1999;19:1011-1018.
22. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996;24: 6-9.
23. Reiser M, Marousis CG, Nelson DR, Lauer G, Gonzalez-Peralta RP, Davis GL, Lau JY. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J. Hepatol. 1997;26:471-478.
24. Lechmann M, Woitas RP, Langhans B, Kaiser R, Ihlenfeldt HG, Jung G, Sauerbruch T, Spengler U. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J. Hepatol. 1999;31:971-978.
25. Eckels DD, Tabatabail N, Bian TH, Wang H, Muheisen SS, Rice CM, Yoshizawa K, Gill J. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. Hum. Immunol. 1999;60:187-199.
26. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10: 439-449.
27. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001;194:1395-1406.
28. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2002;99:15669-15674.
29. Czarniecki CW, Hamilton EB, Fennie CW, Wolf RL. In vitro biological activities of Escherichia coli-derived bovine interferons-alpha, -beta, and -gamma. J. Interferon Res. 1986;6:29-37.
30. Gomi K, Kimura H, Okabe M, Oka T, Morimoto M. Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta. J. Pharmacobiodyn. 1986;9:871-878.
31. Cheney IW, Lai VC, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JY, Tam RC. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J. Virol. 2002;76:11148-11154.
32. Sainz B Jr, Halford WP. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J. Virol. 2002;76:11541-11550.
33. Larkin J, Jin L, Farmen M, Venable D, Huang Y, Tan SL, Glass JI. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J. Interferon Cytokine Res. 2003;23:247-257.
34. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27-55.
35. McClintick JN, Jerome RE, Nicholson CR, Crabb DW, Edenberg HJ. Reproducibility of oligonucleotide arrays using small samples. BMC Genomics 2003;4:4.
36. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic IFN-α species, consensus interferon. J. Interferon Cytokine Res. 1996;16:489-499.
37. Chang TT, Chou TC. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr. Taiwan 2000;41:294-302.
38. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, Gale M Jr. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 2003;77:3898-3912.
39. Espert L, Degols G, Gongora C, Blondel D, Williams BR, Silverman RH, Mechti N. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J. Biol. Chem. 2003;278:16151-16158.
40. Heim MH. RIG-I: an essential regulator of virus-induced interferon production. J. Hepatol. 2005;42:431-433.
41. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004;5:730-737.
42. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M Jr. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 2005;79:2689-2699.
43. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, Peterson LF, Shuai K, Zhang DE. Protein ISGylation modulates the Jak-Stat signaling pathway. Genes Dev. 2003;17:455-460.
44. Kim KI, Zhang DE. ISG15, not just another ubiquitin-like protein. Biochem. Biophys. Res. Commun. 2003;307:431-434.
45. Kitamura A, Takahashi K, Okajima A, Kitamura N. Induction of the human gene for p44, a hepatitis-C-associated microtubular aggregate protein, by interferon-alpha/beta. Eur. J. Biochem. 1994; 224:877-883.
46. Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001;20: 7274-7286.
47. Sainz B Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004;329:11-17.
48. Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N. Engl. J. Med. 1988;319:146-151.
49. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukocyte Biol. 2001;69:912-920.
50. Barnes B, Lubyova B, Pitha PM. On the role of IRF in host defense. J. Interferon Cytokine Res. 2002;22:59-71.
51. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001;14:778-809.
52. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2002;2:675-687.
53. Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 2005;102:2986-2991.
54. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA 2004;101: 17264-17269.
55. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens. State Sci. Statements 2002;19:1-46.
56. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Intern. Med. 2004;140:370-381.
57. Melen K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J. Hepatol. 2000;33:764-772.
58. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 2001;75:1252-1264.
59. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int. Rev. Immunol. 1998;16:205-226.
60. Agostini C, Trentin L, Sancetta R, Facco M, Tassinari C, Cerutti A, Bortolin M, Milani A, Siviero M, Zambello R, Semenzato G. Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Blood 1997;90:1115-1123.
61. Taylor MW, Grosse WM, Schaley JE, Sanda C, Wu X, Chien SC, Smith F, Wu TG, Stephens M, Ferris MW, McClintick JN, Jerome RE, Edenberg HJ. Global effect of PEG-IFN-α and ribavirin on gene expression in PBMC in vitro. J. Interferon Cytokine Res. 2004;24:107-118.
62. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Suzuki T, Miyagi T, Hayashi N. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J. Immunol. 2003;171:5423-5429.
63. Lenda DM, Kikawada E, Stanley ER, Kelley VR. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J. Immunol. 2003;170:3254-3262.
64. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-151.
65. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 1993;268:14245-14249.
66. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds betal integrins, collagens and fibronectin. EMBO J. 1998;17:1606-1613.
67. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 1994;269:18401-18407.
68. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, Ishihara K. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995;26:527-534.
69. Radaeva S, Jaruga B, Kim WH, Heller T, Liang TJ, Gao B. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of Stal1 induction and hyperexpression of Stal1 in chronic hepatitis C. Biochem. J. 2004;379:199-208.
70. Prabhakar U, Eirikis E, Reddy M, Silvestro E, Spitz S, Pendley C, Davis HM, Miller BE. Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J. Immunol Methods 2004;291:27-38.
71. Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002;13:441-454.
72. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J. Interferon Cytokine Res. 2002;22:39-47.